Avita Medical (RCEL) announced the U.S. commercial launch of Cohealyx, a collagen-based dermal matrix branded by Avita Medical and co-developed with Regenity Biosciences. Cohealyx is designed to facilitate cellular migration and revascularization, thereby providing an ideal wound bed for definitive closure. In pre-clinical and initial clinical utilization, an integrated wound bed was seen as early as seven days.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCEL:
- Avita Medical’s Strategic Expansion and Market Growth Potential: Analyst Buy Rating
- Avita Medical Boosts Production with New Agreement
- Avita Medical amends PermeaDerm distribution agreement with Stedical Scientific
- Avita Medical management to meet with Lake Street
- Avita Medical price target lowered to $22 from $25 at D. Boral Capital